Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $314.00
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target boosted by Bank of America from $307.00 to $314.00 in a research report sent to investors on Monday, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. ALNY has been the topic of a number of other research reports. TD Cowen […]
More Stories
Stifel Nicolaus Downgrades Kura Oncology (NASDAQ:KURA) to Hold
Stifel Nicolaus downgraded shares of Kura Oncology (NASDAQ:KURA – Free Report) from a buy rating to a hold rating in...
The Goldman Sachs Group Increases eBay (NASDAQ:EBAY) Price Target to $55.00
eBay (NASDAQ:EBAY – Free Report) had its price target hoisted by The Goldman Sachs Group from $46.00 to $55.00 in...
Cognizant Technology Solutions (NASDAQ:CTSH) Upgraded at StockNews.com
StockNews.com upgraded shares of Cognizant Technology Solutions (NASDAQ:CTSH – Free Report) from a hold rating to a buy rating in...
StockNews.com Downgrades Cimpress (NASDAQ:CMPR) to Buy
StockNews.com lowered shares of Cimpress (NASDAQ:CMPR – Free Report) from a strong-buy rating to a buy rating in a research...
Nurix Therapeutics (NASDAQ:NRIX) Given Overweight Rating at Stephens
Stephens restated their overweight rating on shares of Nurix Therapeutics (NASDAQ:NRIX – Free Report) in a research report sent to...
Leerink Partners Initiates Coverage on Mind Medicine (MindMed) (NASDAQ:MNMD)
Leerink Partners began coverage on shares of Mind Medicine (MindMed) (NASDAQ:MNMD – Free Report) in a report released on Monday,...